As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.
The strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. It also positions the company on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others.
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
Biogen gained exclusive ex-U.S. rights to Ampyra in 2009 and is selling the drug under the brand name Fampyra in international markets.
Governments have struggled to communicate the risks still posed by COVID and the benefits of vaccination since a global public health emergency was declared over in May 2023.
Several experts on a panel Wednesday at JPM’s Biotech Showcase expressed positive attitudes for the coming year on the investment side, with the industry showing “signs of life”.
A new study published in the BMJ found strong financial ties between the pharmaceutical industry and physicians serving as panelists and task force members of the DSM-5.
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk’s Wegovy and Zepbound from Eli Lilly .
The claims allege that the drugmaker’s tenofovir, an antiretroviral used in Gilead’s older HIV drugs, caused kidney, tooth, or bone damage to patients, and that Gilead knew its tenofovir-based drugs which were still in development, were safer.
According to a survey from August, nearly a third of U.S. hospital pharmacists said that they were forced to ration, delay or cancel treatments as drug shortages in the country approach an all-time high.